Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from PBAC

One-size-fits-all AI guardrails do not work in the enterprise

One-size-fits-all AI guardrails are out. The future of enterprise AI safety is Persona-Based Access Controls.

TechRadar

What is lecanemab, the newly approved Alzheimer’s drug? Can it really slow down dementia?

Dementia is a condition that results in progressive memory or thinking problems. It’s now the most common cause of death in Australia. There are many different causes of dementia, but Alzheimer’s disease accounts for around 60–80% of all cases.

The Conversation

Will the US trade war push up the price of medicines in Australia? Will there be drug shortages?

Talks of a trade dispute between the United States and Australia over the cost of medicines have no doubt left many Australians scratching their heads.

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

US Pharma Lobby Targets Australia's AU$18B PBS, Urges Trump To Impose Punitive Tariffs

On March 11, a formal complaint was submitted to US Trade Representative Jamieson Greer, urging the Trump administration to take strong action against Australia's "damaging pricing policies."

International Business Times

England subsidises drugs like Ozempic for weight loss. Could Australia follow?

People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity. This includes Wegovy (the weight-loss dose of Ozempic, or semaglutide) and Mounjaro (one of the brand names for tirzepatide).

The Conversation

Moderna’s mRNA vaccines to be exempt from advisory committee scrutiny under $2bn Morrison-era deal

Exclusive: Critics say exemption ‘deeply concerning’ and risks creating separate assessment systems

The Guardian - AU

This virus nearly killed the AMA chief's son. Yet vaccines remain out of reach

His son, Tim, was afflicted with the virus as a toddler.

The Canberra Times

Read news from The Economist, FT, and more,
with one subscription

TGA approves new medication for treatment of endometriosis symptoms

Australian drug regulator gives company green light for tablet – although it won’t be subsidised by Pharmaceutical Benefits Scheme

The Guardian - AU

The Pharmacy Guild of Australia says the government's 60-day script policy will worsen medicine shortages. What does the data say?

The Pharmacy Guild of Australia says 400 drugs are on the "critical" shortage list and 20 per cent of those would be out of stock due to the government's new 60-day script policy. But the data tells a different story.

ABC News

Despite tears and panic from the pharmacy lobby, Labor’s medicine reforms won’t cause the world to end

In the interests of reassuring the community, let’s address each of the alarm bells set off by the Pharmacy Guild

The Guardian - AU

Scientists push to change COVID-19 antiviral guidelines to make medication more accessible in Australia

Some scientists say Australia's guidelines on who can get antivirals is too restrictive. But the federal health department says our use of antivirals is only marginally less than the US.

ABC News

As some experts and long-COVID sufferers call for antivirals to be more accessible, others say the science isn't proven yet

Some long COVID sufferers are paying thousands of dollars for COVID-19 antivirals, hoping they will lessen their symptoms during reinfections. While some experts say it's time to allow more Australia access to subsidised medications, others say more research is needed.

ABC News

Calls to expand access to Covid antivirals in Australia splits experts and doctors

Health minister encourages Paxlovid and Lagevrio use, but peak GP body cautions Paxlovid can have side-effects if taken with some other drugs

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Labor

11,987 stories

the Trump Administration

the Pharmaceutical Benefits Scheme

13 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.